AB001 is a novel PSMA-targeted radioligand therapy designed to treat metastatic prostate cancer with potentially higher tumor dose rates and lower normal tissue toxicity. The phase 1 trial will enroll ...

William C. Huang, MD, highlights data from a long-term extension study of the OPTIMA II trial. In a recent interview with Urology Times®, William C. Huang, MD, outlined the key findings and ...

IDE397 combined with sacituzumab govitecan showed promising efficacy in MTAP-deletion urothelial carcinoma, with high disease control rates in both dose cohorts. The combination therapy's efficacy ...

Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical advice.